Arbutus Biopharma Corp SEC filings ABUS
Arbutus Biopharma Corp has 1,000 filings in SEC EDGAR's recent list, going back to Aug 9, 2011. Its latest annual report, Form 10-K, was filed on Mar 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 22, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 14, 2026 | — |
| DEF 14A | Proxy statement | Apr 14, 2026 | May 26, 2026 |
| DEFA14A | Additional proxy material | Apr 4, 2025 | — |
| DEF 14A | Proxy statement | Apr 4, 2025 | May 21, 2025 |
| DEFA14A | Additional proxy material | Apr 10, 2024 | — |
| DEF 14A | Proxy statement | Apr 10, 2024 | May 22, 2024 |
| DEFA14A | Additional proxy material | Apr 12, 2023 | — |
| DEF 14A | Proxy statement | Apr 12, 2023 | May 24, 2023 |
| DEFA14A | Additional proxy material | Apr 11, 2022 | — |
| DEF 14A | Proxy statement | Apr 11, 2022 | May 25, 2022 |
| DEFA14A | Additional proxy material | Apr 8, 2021 | — |
| DEF 14A | Proxy statement | Apr 8, 2021 | May 26, 2021 |
| DEF 14A | Proxy statement | Apr 24, 2020 | May 28, 2020 |
| DEF 14A | Proxy statement | Apr 23, 2019 | May 22, 2019 |
| DEF 14A | Proxy statement | Apr 25, 2018 | Apr 23, 2018 |
| DEFA14A | Additional proxy material | Dec 12, 2017 | — |
| DEF 14A | Proxy statement | Dec 6, 2017 | Dec 6, 2017 |
| PRE 14A | Preliminary proxy statement | Nov 2, 2017 | Oct 25, 2017 |
| DEFA14A | Additional proxy material | Oct 17, 2017 | — |
| DEFA14A | Additional proxy material | Oct 3, 2017 | — |
| DEFA14A | Additional proxy material | Apr 18, 2017 | — |
| DEF 14A | Proxy statement | Apr 18, 2017 | Apr 18, 2017 |
| DEFA14A | Additional proxy material | Apr 8, 2016 | — |
| DEF 14A | Proxy statement | Apr 8, 2016 | May 19, 2016 |
| DEF 14A | Proxy statement | May 29, 2015 | Jul 9, 2015 |
| PRE 14A | Preliminary proxy statement | May 4, 2015 | Jun 25, 2015 |
| DEFA14A | Additional proxy material | Feb 26, 2015 | — |
| DEFA14A | Additional proxy material | Feb 11, 2015 | — |
| DEFA14A | Additional proxy material | Feb 5, 2015 | — |
| DEFM14A | Filing | Feb 4, 2015 | — |
| DEFA14A | Additional proxy material | Jan 28, 2015 | — |
| DEFA14A | Additional proxy material | Jan 26, 2015 | — |
| PREM14A | Filing | Jan 23, 2015 | Jan 23, 2015 |
| DEFA14A | Additional proxy material | Jan 12, 2015 | — |
Showing 34 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ABUS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Warminster, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1447028
- Former names
- TEKMIRA PHARMACEUTICALS CORP (until Aug 3, 2015); TEKMIRA PHARMACEUTICALS Corp (until Aug 3, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.